Clinical Utility of Inflammatory Markers & Advanced Lipoprotein Testing: Advice from Lipid Specialists

Last Updated: Tuesday, 04-Oct-2011 16:00:00 EDT

The NLA held a consensus conference in January 2011 to bring together experts on inflammatory markers and advanced lipoprotein testing for the generation of an NLA statement of clinical guidance regarding the utility of various biomarkers. The panel reviewed apolipoprotein B (Apo B), C-reactive protein (CRP), high-density lipoprotein (HDL) subfractions, lipoprotein-associated phospholipase A2 (Lp-PLA2), low-density lipoprotein (LDL) subfractions, low-density lipoprotein particle number/concentration (LDL-P), and lipoprotein (a) (Lp(a)). Click here to view the statement of the NLA expert panel, published in the October 2011 edition of the Journal of Clinical Lipidology.